🏛️ Verified NIH Record • Updated 2026-04-17
A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma (NCT07288203)
A Phase 2, Multicenter, Open-label Study of Lifileucel (Tumor-infiltrating Lymphocytes [TIL]) in Participants With Previously Treated Advanced Melanoma
🔵 Active, Not Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Iovance Biotherapeutics, Inc.
🩺 Plain-English Summary (8th-Grade Level)
This is a Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes \[TIL\]) in participants with previously treated advanced melanoma
Who can join: Review the eligibility criteria below.
Location: Sarah Cannon Research Institute — Nashville, Tennessee
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- Sarah Cannon Research Institute — Nashville, Tennessee
- Greenslopes Private Hospital — Greenslopes, Queensland
- Princess Margaret Cancer Centre — Toronto, Ontario, Canada
- Centre Hospitalier de l'Universite de Montreal — Montral, Quebec, Canada
- Royal Marsden Hospital — London,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Melanoma (Skin Cancer)
- Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade — New York, New York
- NeoAdjuvant, Spare-Adjuvant (NASA) in Stage IIIB-IV (M1a) Melanoma — Chapel Hill, North Carolina
- Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors — Tucson, Arizona
- Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions — Chicago, Illinois
- Phase Ib Study of AlpeliSib With PEmbroLizumab in Patients With mEtastatic Breast caNcer or melanomA (SELENA) — Houston, Texas
Explore by condition: All Melanoma (Skin Cancer) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.